ClinicalTrials.gg
CompletedNCT05131594LCRCUpdated Oct 20, 2026

Evaluating the Response of the Immune System of People With Long COVID (Post SARS-CoV-2)

An observational study in COVID-19, sponsored by Huntington Memorial Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Primary conditionPost-Acute COVID-19 SyndromeRegistry: COVID-19ReclassifiedWhy we changed it
Registry
COVID-19 — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Acute COVID-19 Syndrome
Why
  1. The study's title name Post-Acute COVID-19 Syndrome, a narrower term within COVID-19.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Huntington Memorial Hospital · Observational

How we know

Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
59
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Enrollment
28th of 37
59 · median 155
Started
2021
with 18 others
Observational
37 of 195
15 open now
Registered
28th of 195
by date

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 28th largest by enrollment of the 37 observational ones that give a count, is one of 19 that started in 2021, is one of 37 observational ones, and was the 28th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

Many people who have had COVID 19 continue to experience symptoms long after they have recovered from the acute infection. This study will examine the clinical symptoms of people with "Long COVID" and measure various markers of inflammation in their blood.

Read the detailed description

Patients who attend the Long Covid Recovery Clinic at Huntington Hospital will be offered participation in the study. After giving written informed consent, their medical history along with a description of clinical symptoms given through an extensive questionnaire will be accessed. Venous blood will be collected as a baseline and then at follow up visits (as dictated by changes in clinical symptomatology) for evaluation of corollary immune parameters. Patients will be followed at a minimum of every 2 months for 2 years.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • post-acute sequelae of SARS-CoV2
  • post-acute COVID-19 syndrome
  • long COVID
04

In context

Post-Acute COVID-19 Syndrome Reclassified

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's enrollment of 59 is below the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Huntington Memorial Hospital is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (18 years old or older) who enroll in Huntington Hospital's Long Covid Recovery Clinic will be offered but are under no obligation to participate in this study. Subjects will have documented previous infection with SARS-CoV2 and symptoms suggestive of post-acute sequelae of SARS-CoV2 (including but not limited to chronic fatigue, brain fog, muscle and joint pain, cardiac and pulmonary issues, or other factors related to their acute COVID-19 event).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled in Huntington Hospital\'s Long Covid Recovery Clinic
  • Documented previous infection with SARS-CoV2
  • Symptoms suggestive of post-acute sequelae of SARS-CoV2 (including but not limited to chronic fatigue, brain fog, muscle and joint pain, cardiac and pulmonary issues, or other factors related to their acute COVID-19 event)
  • Signed Form

Exclusion criteria

Exclusion Criteria:

  • No documented positive SARS-CoV2 serologies
  • No post-acute sequelae of SARS-CoV2 symptomatology
  • Incarcerated
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
59 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
07

What researchers measure

Primary outcomes

  1. Correlation of symptomatology with inflammatory profiles in patients with Post-Acute Sequelae of SARS-CoV2 (PASC)

    Do patient symptoms correlate with abnormalities in inflammatory profiles?

    Time frame: From onset of infection to 24 months

  2. Identification of immunologic and inflammatory features of PASC based on results of immunologic and inflammatory assays

    Are there abnormalities in immunologic and inflammatory assays unique to PASC?

    Time frame: From onset of infection to 24 months

  3. Evaluation and delineation of the pathologic pathways and long-term effects of SARS-CoV2 infection

    What are the pathological pathways and long-term effects of SARS-CoV2?

    Time frame: From onset of infection to 60 months

  4. Identification of risks factor for PASC

    What are the risk factors for PASC?

    Time frame: From onset of infection to 24 months

  5. Identification of potential sites of therapeutic intervention to ameliorate symptomatology of PASC

    Are there potential sites of therapeutic intervention to relieve the symptoms of PASC?

    Time frame: From onset of infection to 60 months

08

Study locations

1 site
  • Huntington Hospital
    Pasadena, California 91105, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2024, 36 months.

Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's 36 months is above that.

Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2025 → Oct 2024 and completion Jun 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Nov 23, 2021
StartActual
Oct 13, 2021
Primary completionActual
Oct 31, 2024was Jun 2025
CompletionActual
Aug 21, 2026was Jun 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 20, 2026
Primary completion
Jun 2025→Oct 31, 2024 (actual)
Oct 20, 2026
Study completion
Jun 2026→Aug 21, 2026 (actual)
Oct 20, 2026
Enrollment
100 (estimated)→59 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Enrolling by invitation→Completed
    Primary completion Jun 2025→Oct 31, 2024 (now actual)
    Study completion Jun 2026→Aug 21, 2026 (now actual)
    Enrollment 100 (estimated)→59 (actual)
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05131594
Lead sponsor
Huntington Memorial Hospital
Collaborators
San Diego Biomedical Research Institute
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Oct 13, 2021
Primary completion
Oct 31, 2024
Completion
Aug 21, 2026
Last update
Oct 20, 2026

Study contacts

Kimberly Shriner, MD
principal investigator · Huntington Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion